NOVADAQ to Participate in the RBC Capital Markets 2016 Global Healthcare Conference
10 February 2016 - 8:30AM
Novadaq Technologies Inc. ("NOVADAQ" or the “Company")
(NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of
clinically relevant fluorescence imaging solutions for use in
surgical and diagnostic procedures, announced today that management
will participate in a fireside chat presentation at the RBC Capital
Markets 2016 Global Healthcare Conference on Tuesday, February 23,
2016 at 11:30 a.m. Eastern Time at the Palace Hotel in New York,
NY.
The presentation will be webcast live and
archived for 90 days on the Company's website at
http://www.novadaq.com under the "Events" tab in the Investors
section.
About Novadaq Technologies
Inc.
Enabling medical professionals with clinically
relevant, point-of-care imaging solutions to enhance the lives of
patients and their caregivers, while reducing health care costs, is
NOVADAQ’s global mission. SPY fluorescence imaging technology
provides surgeons with real-time visualization, leading to improved
outcomes and reduced costs without exposing the patient to
radiation. More than 150 peer-reviewed publications demonstrate
that the use of SPY imaging technologies during complex surgery and
diagnostic procedures, leads to lower rates of post-operative
complications and lower hospital costs.
SPY Imaging Systems are United States Food and
Drug Administration 510(k) cleared for use in seven surgical
specialties. The endoscopic version of SPY called PINPOINT,
combines the capabilities of SPY Imaging with high definition
(“HD”) visible light visualization offered by conventional
endoscopes. LUNA is used to assess perfusion in patients being
treated for non-healing wounds. In December 2014, NOVADAQ and
LifeNet Health jointly announced the signing of a multi-year
agreement appointing NOVADAQ the exclusive worldwide distributor of
LifeNet Health’s DermACELL acellular tissue products for wound and
breast reconstruction surgery.
Forward-Looking
Statements
Certain statements included in this press
release may be considered forward-looking. Such statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
NOVADAQ’s current beliefs as well as assumptions made by and
information currently available to NOVADAQ and relate to, among
other things, the Company’s strategy, strategic goals, research and
development activities, research and clinical testing outcomes,
taxes, capital expenditures, future operations, future financial
position, future revenues/results, projected costs, prospects and
plans and objectives of management.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by NOVADAQ in its
public securities filings available at www.sec.gov and
www.sedar.com, actual events may differ materially from current
expectations. NOVADAQ disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
NOVADAQ, SPY, PINPOINT and LUNA are registered
trademarks of Novadaq Technologies Inc. DermACELL is a registered
trademark of LifeNet Health.
For more information, please contact:
Stephen Kilmer
Investor Relations
1-647-872-4849
skilmer@novadaq.com
Novadaq Technologies (NASDAQ:NVDQ)
Historical Stock Chart
From Apr 2024 to May 2024
Novadaq Technologies (NASDAQ:NVDQ)
Historical Stock Chart
From May 2023 to May 2024